Charles Schwab Investment Management Inc. Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Charles Schwab Investment Management Inc. boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 273,135 shares of the company’s stock after buying an additional 38,944 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.52% of Janux Therapeutics worth $14,624,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $139,000. Chicago Capital LLC purchased a new position in Janux Therapeutics during the fourth quarter worth approximately $230,000. Legato Capital Management LLC purchased a new position in Janux Therapeutics during the fourth quarter worth approximately $347,000. Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics in the third quarter valued at approximately $317,000. Finally, Virtu Financial LLC increased its position in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. BTIG Research increased their target price on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partners increased their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $92.44.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,002 shares of company stock valued at $2,684,703 over the last ninety days. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Price Performance

JANX stock opened at $30.43 on Friday. Janux Therapeutics, Inc. has a 1 year low of $28.92 and a 1 year high of $71.71. The firm has a market capitalization of $1.80 billion, a PE ratio of -26.01 and a beta of 3.23. The business has a 50 day simple moving average of $37.22 and a 200-day simple moving average of $46.56.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.